Literature DB >> 6247970

Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.

W H Hall, B J Opfer, D N Gerding.   

Abstract

A total of 91 multiply resistant bacterial strains, including Klebsiella pneumoniae (32 strains), Pseudomonas aeruginosa (16 strains), and Serratia marcescens (43 strains), were collected during hospital epidemics of nosocomial infection from 1975 to 1979. These strains were resistant to gentamicin, tobramycin, cephalothin, chloramphenicol, and ampicillin. Their susceptibility to three new broad-spectrum beta-lactams, LY127935 (a 1-oxa-beta-lactam), cefotaxime (HR 756), and cefoperazone (T 1551), was compared with the susceptibility of random strains of nine species of aerobic gram-negative bacilli collected in the same hospital in 1979. Susceptibility to cefamandole and ticarcillin was also determined. Strains of staphylococci and streptococci from that hospital and two nearby city-county hospitals were also compared for the three new cephalosporins and other effective antibiotics. The agar dilution method was used to measure the minimum inhibitory concentration for each antibiotic. The multiply resistant strains (minimum inhibitory concentration for gentamicin >/= 8 mug/ml) usually were as susceptible to the three new broad-spectrum beta-lactams as were non-multiply resistant strains. Both Klebsiella pneumoniae and Serratia marcescens, including multiply resistant and non-multiply resistant strains, were most susceptible to the 1-oxa-beta-lactam LY127935 and cefotaxime. P. aeruginosa (both multiply resistant and non-multiply resistant strains) were most susceptible to cefoperazone. All three new beta-lactams were active against non-multiply resistant strains of Escherichia coli, Enterobacter spp., Proteus spp., and Citrobacter spp. Providencia stuartii were most susceptible to cefotaxime and the 1-oxa-beta-lactam LY127935. The three new beta-lactams were all less active against staphylococci (especially methicillin-resistant Staphylococcus aureus) than cephalothin. Streptococcus pyogenes and S. pneumoniae were very susceptible to cefotaxime and cefoperazone, though less susceptible to LY127935. None of the three new beta-lactams was active against S. faecalis. All were very active against both penicillinase-positive and -negative strains of Neisseria gonorrhoeae.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247970      PMCID: PMC283771          DOI: 10.1128/AAC.17.2.273

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro activity of HR 756, a new cephalosporin compound.

Authors:  P M Shah; G Troche; W Stille
Journal:  J Antibiot (Tokyo)       Date:  1978-11       Impact factor: 2.649

2.  Comparative susceptibility of penicillinase-positive and -negative Neisseria gonorrhoeae to 30 antibiotics.

Authors:  W H Hall; E A Schierl; J E Maccani
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

3.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

6.  Nosocomial multiply resistant Klebsiella pneumoniae: epidemiology of an outbreak of apparent index case origin.

Authors:  D N Gerding; A E Buxton; R A Hughes; P P Cleary; J Arbaczawski; W E Stamm
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

7.  LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

8.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

9.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

  9 in total
  39 in total

1.  Determination of cefoperazone concentration in serum and muscle tissue with a versatile high-pressure liquid chromatographic method.

Authors:  R R Muder; W F Diven; V L Yu; J Johnson
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

2.  Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.

Authors:  M Joshi; W C Anthony; J H Tenney; G L Drusano; E S Caplan; H C Standiford; A Henson; J W Warren
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  Epidemiology of gentamicin-resistant, gram-negative bacillary colonization in a spinal cord injury unit.

Authors:  D M Shlaes; C A Currie; G Rotter; M Eanes; R Floyd
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

4.  In vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates.

Authors:  G M Eliopoulos; A Gardella; P DeGirolami; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Moxalactam therapy of serious infections.

Authors:  P Van der Auwera; N Clumeck; Y Van Laethem; R Vanhoof; J P Butzler
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

6.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

7.  Cephalosporins: recent developments.

Authors:  A Kumar
Journal:  J Natl Med Assoc       Date:  1983-02       Impact factor: 1.798

8.  The use of moxalactam in the treatment of serious infections due to multi-resistant organisms.

Authors:  S Srinivasan; E L Francke; C Ortiz-Neu; A S Prince; H C Neu
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

9.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

10.  Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.

Authors:  C R Magnussen; M T Sammartino; K D Ernest
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.